Jupiter Topco LLC Invests $75.94 Million in Becton, Dickinson and Company $BDX

Jupiter Topco LLC acquired a new stake in shares of Becton, Dickinson and Company (NYSE:BDX) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 501,872 shares of the medical instruments supplier’s stock, valued at approximately $75,944,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of BDX. Ancora Advisors LLC increased its position in Becton, Dickinson and Company by 1.8% in the 2nd quarter. Ancora Advisors LLC now owns 5,967 shares of the medical instruments supplier’s stock worth $903,000 after purchasing an additional 106 shares during the last quarter. Canada Pension Plan Investment Board lifted its holdings in shares of Becton, Dickinson and Company by 190.4% during the 2nd quarter. Canada Pension Plan Investment Board now owns 162,430 shares of the medical instruments supplier’s stock valued at $24,581,000 after buying an additional 106,488 shares during the last quarter. Legal & General Group Plc grew its stake in shares of Becton, Dickinson and Company by 1.5% in the 2nd quarter. Legal & General Group Plc now owns 2,101,695 shares of the medical instruments supplier’s stock valued at $318,050,000 after buying an additional 30,766 shares in the last quarter. Palliser Capital UK Ltd acquired a new position in Becton, Dickinson and Company in the second quarter worth approximately $2,048,000. Finally, Manning & Napier Advisors LLC increased its holdings in Becton, Dickinson and Company by 10.5% in the second quarter. Manning & Napier Advisors LLC now owns 34,426 shares of the medical instruments supplier’s stock worth $5,343,000 after buying an additional 3,278 shares during the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Down 1.1%

Becton, Dickinson and Company stock opened at $188.11 on Friday. The firm has a market capitalization of $51.83 billion, a PE ratio of 56.66, a PEG ratio of 13.41 and a beta of 0.19. The business’s 50-day simple moving average is $165.23 and its 200-day simple moving average is $160.33. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $193.07.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, topping the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The company had revenue of $4.98 billion for the quarter, compared to the consensus estimate of $4.89 billion. During the same period in the previous year, the business posted $3.68 EPS. The company’s revenue for the quarter was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Equities research analysts forecast that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be given a dividend of $1.05 per share. The ex-dividend date of this dividend is Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a yield of 2.2%. Becton, Dickinson and Company’s payout ratio is 126.51%.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on BDX. Weiss Ratings reiterated a “sell (d+)” rating on shares of Becton, Dickinson and Company in a research note on Friday, August 7th. Wells Fargo & Company raised their price target on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the company an “equal weight” rating in a report on Friday, August 7th. Royal Bank Of Canada lifted their price objective on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a “sector perform” rating in a research note on Thursday, August 13th. Bank of America cut their target price on Becton, Dickinson and Company from $177.00 to $170.00 in a report on Friday, June 12th. Finally, Barclays boosted their price target on Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. Eight investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $185.67.

Insider Activity at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 1,100 shares of the business’s stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total transaction of $160,226.00. Following the transaction, the executive vice president owned 13,172 shares in the company, valued at approximately $1,918,633.52. The trade was a 7.71% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 4,152 shares of the company’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $185.00, for a total transaction of $768,120.00. Following the transaction, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at $20,380,155. This represents a 3.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 11,869 shares of company stock valued at $1,994,719 in the last 90 days. 0.40% of the stock is owned by company insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.